From starvation to time-restricted eating: a review of fasting physiology
October 5, 2024 / Intermittent Fasting Benefits / Ketone Bodies Metabolism / Starvation Adaptation
This review explores the physiology of starvation and intermittent fasting, highlighting the metabolic role of ketone bodies and their benefits. It emphasizes the need for further study into the mechanisms behind the metabolic effects of intermittent fasting.
Association between asthma and visceral adipose tissue in adults, a cross-sectional study from NHANES 2011–2018
September 27, 2024 / Obesity Risk / Asthma Risk / Visceral Adipose Tissue
This study, using NHANES data, found a significant association between increased visceral adipose tissue (VAT) and asthma risk in adults. Higher VAT, especially in females and older adults, increased asthma risk, emphasizing the need to consider VAT in asthma management.
Overcoming pediatric obesity: Behavioral strategies and GLP-1 support
October 4, 2024 / Obesity Treatment / Behavioral Weight Loss / GLP-1 Agonists / Childhood Obesity
Dr. Kay Rhee discusses pediatric obesity treatment, emphasizing the challenges of genetic and environmental factors. She highlights the role of behavioral interventions and GLP-1 agonists in managing obesity by helping children build healthier habits while controlling cravings.
Time-Restricted Eating Tightens Glycemic Control in Patients With Metabolic Syndrome
October 4, 2024 / TRE Metabolic Syndrome Benefits / Cardiometabolic Health / Weight Loss Time-restricted eating
A study found time-restricted eating (TRE) improves glycemic control and weight loss in patients with metabolic syndrome, outperforming standard care over three months. TRE showed reductions in HbA1c, body fat, and cholesterol, offering cardiometabolic benefits.
Balancing health: diabetes and obesity increase risk of liver cancer relapse
October 3, 2024 / Liver Cancer Recurrence / Obesity / Diabetes
Obesity and diabetes significantly increase the risk of liver cancer recurrence after surgery. A study found a 3.8 times higher recurrence risk with obesity and 2 times higher with diabetes, emphasizing the need for managing these conditions postoperatively.
Structure-function analysis of time-resolved immunological phases in metabolic dysfunction-associated fatty liver disease (MASH) comparing the NIF mouse model to human MASH
October 3, 2024 / MASH Immunological Phases / MASH Fibrosis Treatment / Liver Disease
This study compared immunological phases of metabolic dysfunction-associated steatohepatitis (MASH) in the NIF mouse model to human MASH, revealing similarities in inflammatory and fibrotic responses. The findings highlight potential immunological targets for future treatments.
The Unexpected Sign of Metabolic Syndrome Most People Miss, According to Cardiologists
October 3, 2024 / Metabolic Syndrome Symptoms / Preventing Metabolic Syndrome / Heart Disease Risk Factors
Metabolic syndrome affects one in three Americans, increasing heart disease risk. Many miss its symptoms, which include high blood pressure, blood sugar, and excess abdominal fat. Cardiologists emphasize its preventability and reversibility through awareness and lifestyle changes.
Metabolic Accelerator Shows Promise for Weight Loss Side of Obesity-HFpEF Equation
October 2, 2024 / HU6 Weight Loss / Metabolic Accelerator Therapy / Obesity Heart Failure / Clinical Trial Results
HU6, a novel metabolic accelerator, showed modest weight loss and adipose reduction in obesity-related HFpEF patients, but lacked significant improvement in exercise capacity and functional biomarkers. Further trials are needed to assess its long-term efficacy.
Scientists discover a new understanding of how an old hormone works, paving way for better therapies for metabolic disease
October 2, 2024 / Glucagon Signaling Liver / Obesity Diabetes Therapies / Glucagon-based Treatments
Monash University researchers discovered how glucagon signals within liver cells via the vesicle trafficking protein SEC22B, revealing new therapeutic possibilities for treating obesity, type 2 diabetes, and fatty liver disease, potentially improving metabolic disease management.
Improving obesity care: New AI technique to predict waist circumference and identify patient obesity risk
October 2, 2024 / Obesity Risk AI Tool / Health Predictor / AI Diabetes Heart Diease Risk
Johns Hopkins engineers developed an AI tool that accurately predicts waist circumference using factors like age, height, weight, and ethnicity. This tool enhances obesity risk assessments, outperforming BMI and aiding in diabetes and heart disease prevention.
Genetic study uncovers key drivers of metabolic syndrome with brain tissue links
October 1, 2024 / Metabolic Syndrome Genetics / MetS Brain Tissue Link
A multivariate genetic study identified key drivers of metabolic syndrome (MetS), including 1,650 SNPs and 11 target genes, highlighting brain tissue involvement. Polygenic risk scores showed strong predictive power, and associations with cardiovascular and metabolic diseases were established.
Kailera Therapeutics emerges from stealth with $400M for obesity drugs
October 1, 2024 / Kailera Therapeutics / GLP-1 / Obesity / Drug Development / Clinical Trials / Metabolic Disease Treatments
Kailera Therapeutics launched with $400M to develop GLP-1 drugs for obesity and metabolic diseases. Their lead drug, KAI-9531, targets GLP-1 and GIP receptors and is undergoing clinical trials for obesity and Type 2 diabetes.
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
October 1, 2024 / Denifanstat Breakthrough Therapy / MASH Treatment FDA / Clinical Trials
Sagimet Biosciences received FDA Breakthrough Therapy designation for denifanstat in treating noncirrhotic MASH with moderate to advanced fibrosis (F2-F3). The drug showed significant improvements in fat accumulation, inflammation, and fibrosis in Phase 2b trials.
Genetic study uncovers key drivers of metabolic syndrome with brain tissue links
October 1, 2024 / Metabolic Syndrome Genetics / Brain Tissue Links MetS
A genome-wide study identified 1,307 genetic loci linked to metabolic syndrome (MetS), with significant enrichment in brain tissues. The findings highlight 11 key genes and demonstrate strong predictive power of polygenic risk scores across European and East Asian populations.
Regulating iron overload: Liraglutide’s potential benefits
September 30, 2024 / GLP-1 Agonists Iron Regulation / Iron Overload Diabetes / Obesity Benefits
A study on mice with hereditary hemochromatosis and obesity found that liraglutide, a GLP-1 agonist, improved glucose tolerance, reduced body weight, and potentially regulated iron metabolism, suggesting its therapeutic potential for managing iron overload and related metabolic conditions.
Study proposes new heart failure treatment targeting abnormal hormone activity
September 30, 2024 / HFpEF Glucagon Receptor / Heart Failure Treatment / Glucagon Heart Disease Link / Metabolic Disease / Drug Therapy
Duke-NUS researchers discovered that blocking excessive glucagon activity in heart cells significantly improves heart function in HFpEF. This finding opens new treatment avenues for HFpEF, a challenging heart condition linked to diabetes, obesity, and hypertension.
Time-restricted eating linked to greater blood sugar control and fat loss
September 30, 2024 / Glucose Control TRE / Weight Loss Metabolic Syndrome / Metabolic Health
A study found that time-restricted eating (TRE) combined with nutritional counseling improved glucose control, weight, and fat loss in adults with metabolic syndrome. TRE outperformed standard dietary guidance alone, suggesting it as an effective lifestyle intervention.
One in three Americans has a dysfunctional metabolism, but intermittent fasting could help
September 30, 2024 / Weight Loss Time-restricted Eating / Metabolic Syndrome / Cholesterol Improvement
A clinical trial found time-restricted eating (TRE) improved cardiometabolic health in adults with metabolic syndrome, showing better blood sugar regulation, reduced cholesterol, and weight loss. TRE is a simple, low-cost intervention that complements standard treatments.
Multivariate genomic analysis of 5 million people elucidates the genetic architecture of shared components of the metabolic syndrome
September 30, 2024 / Metabolic Syndrome Genetics / Polygenic Risk / MetS Brain Tissue Link
A multivariate genome-wide study involving nearly 5 million individuals identified 1,307 genetic loci linked to metabolic syndrome (MetS), primarily in brain tissues. The findings highlight key genes and provide insights into the shared genetic architecture influencing MetS components.